281,700 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Bought by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 281,700 shares of the company’s stock, valued at approximately $1,310,000.

Other institutional investors also recently made changes to their positions in the company. Point72 Asset Management L.P. purchased a new stake in GoodRx during the third quarter valued at about $11,295,000. Rubric Capital Management LP raised its stake in shares of GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after purchasing an additional 943,226 shares in the last quarter. Franklin Resources Inc. bought a new position in GoodRx during the 3rd quarter worth approximately $5,675,000. Raymond James Financial Inc. acquired a new position in GoodRx in the fourth quarter worth $2,500,000. Finally, Pier Capital LLC acquired a new position in shares of GoodRx in the 3rd quarter valued at about $3,259,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Mizuho initiated coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Morgan Stanley reduced their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Citigroup cut their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. KeyCorp lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company dropped their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and an average target price of $8.18.

GoodRx Trading Up 6.9 %

GDRX stock opened at $4.79 on Thursday. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a twelve month low of $4.09 and a twelve month high of $9.26. The company has a market cap of $1.84 billion, a P/E ratio of -159.67, a PEG ratio of 2.46 and a beta of 1.25. The business has a fifty day moving average of $4.73 and a 200-day moving average of $5.45.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.